KIT and gastrointestinal stromal tumor: Additionally, various mutations in c-Kit have been linked to different levels of resistance, underlining the necessity of genotyping KIT and PDGFRA to foresee therapeutic outcomes and inform the choice of second-line treatments for GIST patients [31].